Literature DB >> 6167303

The treatment of advanced hodgkin's disease.

D J Straus, B J Lee, B Koziner, L Z Nisce, C W Young, B D Clarkson.   

Abstract

Between January, 1975, and December, 1978, 118 patients with advanced Hodgkin's disease were treated with 8 months of alternating MOPP and adriamycin, bleomycin, dacarbazine and vinblastine (ABDV) combined with 1 month of low-dose radiation therapy (2,000 rad) to areas initially involved with bulky disease. Among 57 evaluable previously-untreated patients, 50/57 (88%) achieved complete and 7/57 (12%) partial remissions. The estimated relapse rate among the complete responders was 16% at 36 months from date of remission. Toxicity was comparable to that of other combination chemotherapy regimens. These results are among the best reported for the treatment of patients with advanced Hodgkin's disease.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6167303     DOI： 10.1007/BF00320472

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  8 in total

1.  Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).

Authors:  A Santoro; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission.

Authors:  E Frei; J K Luce; J F Gamble; C A Coltman; J J Constanzi; R W Talley; R W Monto; H E Wilson; J S Hewlett; F C Delaney; E A Gehan
Journal:  Ann Intern Med       Date:  1973-09       Impact factor: 25.391

3.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

4.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

5.  Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing.

Authors:  R E Dinsmore; D J Straus; M S Pollack; J M Woodruff; T J Garrett; C W Young; B D Clarkson; B Dupont
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

6.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

7.  The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up report.

Authors:  D J Straus; J Myers; S Passe; C W Young; L Z Nisce; B J Lee; B Koziner; Z Arlin; S Kempin; T Gee; B D Clarkson
Journal:  Cancer       Date:  1980-07-15       Impact factor: 6.860

8.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391
  8 in total
  2 in total

Review 1.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

2.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.